PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Lung Disease.
Find out more© Verona Pharma plc 2023. All rights reserved
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.